Unicorn Biotechnologies

Unicorn Biotechnologies is a private, early-revenue stage platform company founded in 2018 and headquartered in Cambridge, UK. It has developed 'Emmet,' a benchtop robotic system that automates cell culture workflows, with a primary focus on iPSC expansion and differentiation to address critical bottlenecks in R&D and manufacturing for cell therapies. The company targets research scientists and laboratory managers, offering both hardware and protocol development services to enhance reproducibility and scalability while reducing labor and contamination risks. Its strategy positions it as an enabler for the broader cell therapy industry rather than a therapeutic developer itself.

Emmet: An intelligent, benchtop robotic system with unified hardware and software that automates cell culture workflows (feeding, passaging, harvesting) for tissue culture flasks. It uses in-line sensing and an AI-driven process control system to standardize and optimize adherent cell culture, starting with iPSCs.

Unicorn operates in the competitive lab automation and bioprocessing equipment space. It competes with large players like Thermo Fisher Scientific, Sartorius, and Lonza who offer broader bioreactor and automation suites, as well as with specialized startups focusing on cell therapy manufacturing tools. Its differentiation lies in its dedicated focus on intelligent, benchtop automation for adherent cell culture (starting with iPSCs) and its integrated protocol development services.